Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) rose 2.3% on Wednesday . The stock traded as high as $7.09 and last traded at $7.00, with a volume of 558,962 shares changing hands. The stock had previously closed at $6.84.

Several research firms have commented on PGNX. Brean Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research note on Friday, May 6th. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Jefferies Group reaffirmed a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. BTIG Research reaffirmed a “buy” rating and set a $9.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, July 20th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Progenics Pharmaceuticals in a research note on Friday, July 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $9.95.

The stock has a 50-day moving average of $6.07 and a 200-day moving average of $5.03. The firm’s market cap is $456.30 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, August 4th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. During the same quarter in the prior year, the business earned ($0.17) earnings per share. The business had revenue of $8.50 million for the quarter, compared to analyst estimates of $6.33 million. The firm’s revenue was up 337.6% on a year-over-year basis. On average, equities analysts forecast that Progenics Pharmaceuticals Inc. will post $0.13 earnings per share for the current fiscal year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.